Target intelligence / Profile preview

Infant gut microbiome modulation (null)

Target
null
Molecular classification
Other
01

Overview

Infant gut microbiome modulation refers to intervention strategies designed to alter the composition and function of the gut microbiota in infants. This may involve approaches such as administering probiotics, prebiotics, synbiotics, or postbiotics; modifying diet (e.g., breastfeeding versus formula feeding); or more experimental approaches like maternal vaginal or fecal microbiota transplantation in cesarean-born infants. These interventions aim to promote beneficial microbial populations (notably Bifidobacterium and Lactobacillus), enhance production of protective metabolites (such as short-chain fatty acids), and support optimal immune, metabolic, and neurodevelopmental outcomes in early life. The field is evolving, with ongoing research into the safety, efficacy, and long-term effects of various modulation strategies, but the term is not used to designate a specific molecular therapeutic target

Other names
Modulation of infant gut microbiomeEarly-life gut microbiota modulationInfant gut microbiota modulation
02

Mechanism of action

Enhancing colonization of beneficial bacteria (e.g., Bifidobacteria via HMOs or probiotics) Inhibiting or displacing pathogenic microbes Modulating immune system maturation via microbial metabolites (e.g., SCFAs, vitamins) Influencing gut-brain axis by shaping microbiome composition and resulting metabolites

03

Biological functions

Immune developmentDigestion and metabolismNeural and cognitive developmentProtection against pathogensShaping long-term health
04

Disease associations

InfectionInflammationAllergic and autoimmune diseasesNeurodevelopmental disordersMetabolic disease (such as obesity, diabetes)
05

Safety considerations

Potential for dysbiosis with inappropriate interventions (e.g., antibiotics)Unknown long-term effects of microbiome transplantationRisk of pathogen transfer in microbiota transplantationIndividualized response; not all infants respond identically
06

Interacting drugs

Probiotics (e.g., Bifidobacterium spp., Lactobacillus spp.)

5 more in the full profile.

07

Biomarkers

Fecal Bifidobacterium abundanceStool pHLevels of short-chain fatty acids (SCFAs)Microbiome diversity and composition assessed by 16S rRNA or metagenomics

Beyond the preview

Go deeper on Infant gut microbiome modulation (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infant gut microbiome modulation (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call